Kymera IPO Presentation Deck

KYMERA E3 Ligase Whole-Body Atlas E3 Ligase Binders Toolbox Ternary Complex Modeling Quantitative System Pharmacology Model Proprietary Chemistry Proprietary Pegasus TPD Platform Key Capabilities Identification of the expression profiles of the approximately 600 unique E3 ligases to match a target protein with the appropriate E3 ligase based on expression, distribution, intracellular localization, and biology. Leveraging the E3 Ligase Whole-Body Atlas, a toolbox of proprietary ligands designed to bind to novel E3 ligases to design protein degraders with specific degradation profiles for different target disease states. Characterization of ternary complex with both structural biology and biophysical techniques feeds a ternary complex modeling tool to optimize the development of highly efficient, and selective degrader therapeutics. A model to measure and predict the diverse sets of parameters that impact protein levels. Based on understanding of PK/PD both in vitro and in vivo, and across different tissues and cell types. Expertise in proprietary chemistry enables the design and optimizes both E3 and target protein binders and convert them into degraders with optimal pharmaceutical properties tailored to specific patient populations and diseases. Proprietary Chemistry E3 Ligase Whole-Body Atlas VPEGASUS Quantitative System Pharmacology Model Ternary Complex Modeling E3 Ligase Binders Toolbar

View entire presentation